De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Biotest Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Peter Janssen

Algemeen directeur

€926.0k

Totale compensatie

Percentage CEO-salaris	47.5%
Dienstverband CEO	2.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Peter Janssen's beloning veranderd ten opzichte van Biotest's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€164m
Mar 31 2024	n/a	n/a	€177m
Dec 31 2023	€926k	€440k	€127m
Sep 30 2023	n/a	n/a	€119m
Jun 30 2023	n/a	n/a	-€10m
Mar 31 2023	n/a	n/a	-€47m
Dec 31 2022	€333k	€147k	-€32m

Compensatie versus markt: De totale vergoeding ($USD 1.03M ) Peter } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.58M ).

Compensatie versus inkomsten: De vergoeding van Peter is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Peter Janssen (56 yo)

2.1yrs

Tenure

€926,000

Compensatie

Mr. Peter Janssen serves as Member of Management Board for Biotest Aktiengesellschaft since September 1, 2022 and served as its Chief Operating Officer since September 2022 until January 2024. He has been...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Janssen	CEO & Chairman of the Board of Management	2.1yrs	€926.00k	geen gegevens
Ainhoa Zubiaga	Member of Management Board & CFO	1.7yrs	€605.00k	geen gegevens
Jorg Schuttrumpf	Chief Scientific Officer & Member of the Management Board	2.8yrs	€707.00k	geen gegevens
Dirk Schuck	Member of Supervisory Board	2.8yrs	€44.00k	geen gegevens
Monika Buttkereit	Head of Investor Relations	no data	geen gegevens	geen gegevens
Christina Erb	Head of Corporate HR	9.2yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIO3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dirk Schuck	Member of Supervisory Board	2.4yrs	€44.00k	geen gegevens
Uta Kemmerich-Keil	Member of Supervisory Board	2.4yrs	€55.00k	geen gegevens
Raimon Grifols Roura	Member of Supervisory Board	1.4yrs	€29.00k	geen gegevens
Bernhard R. Ehmer	Chairman of the Supervisory Board	2.4yrs	€132.00k	geen gegevens
David Bell	Member of Supervisory Board	2.3yrs	€44.00k	geen gegevens
Jurgen Heilmann	Employee Representative Member of Supervisory Board	13.1yrs	€44.00k	geen gegevens

2.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIO3 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Biotest Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest AG Announces Board Changes

Recent updates

Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)

Upcoming dividend of €0.08 per share

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analyst expectations

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

New major risk - Financial position

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

First quarter 2022 earnings: Revenues in line with analyst expectations

Biotest AG Announces Board Changes

Upcoming dividend of €0.04 per share

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Consensus forecasts updated

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Consensus forecasts updated

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Price target increased to €38.93

Third quarter 2021 earnings released

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)

Upcoming dividend of €0.04 per share

Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)

Consensus forecasts updated

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

New 90-day high: €28.80

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €28.50

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Third quarter 2020 earnings released: €0.39 loss per share

Analysts update estimates

New 90-day high - €24.90

First half earnings released

New 90-day high - €22.30

New 90-day high - €21.30

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur